Working... Menu

Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02857361
Recruitment Status : Completed
First Posted : August 5, 2016
Last Update Posted : August 19, 2016
Information provided by (Responsible Party):
iX Biopharma Ltd.

Brief Summary:
The study will look at whether it is preferable to administer two wafers simultaneously or separately.

Condition or disease Intervention/treatment Phase
Pain Drug: Sublingual ketamine wafers Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Two-way Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols in Healthy Volunteers Under Fasted Conditions.
Study Start Date : July 2016
Actual Primary Completion Date : August 2016
Actual Study Completion Date : August 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Ketamine

Arm Intervention/treatment
Experimental: Treatment A: Simultaneous Administration
Sublingual ketamine 50mg (2 x 25mg wafers) administered simultaneously at T=0 minute.
Drug: Sublingual ketamine wafers
Two sublingual ketamine 25 mg wafers
Other Name: Wafermine

Experimental: Treatment B: Sequential Administration
Sublingual ketamine 50mg (2 x 25mg wafers) administered sequentially, one 25 mg wafer at T=0 minute and one 25 mg wafer at T=3 minutes.
Drug: Sublingual ketamine wafers
Two sublingual ketamine 25 mg wafers
Other Name: Wafermine

Primary Outcome Measures :
  1. Bioavailability [ Time Frame: 10 hours ]
    Plasma concentrations collected for 10 hours after simultaneous wafer administration and sequential wafer administration

Secondary Outcome Measures :
  1. Number of treatment related adverse events [ Time Frame: From time of initial dose until 3 days after final dose. ]
  2. Participant Acceptance [ Time Frame: 20 minutes ]
    Participant will rate their experience by completing a questionnaire 20 minutes after each dose.

  3. Administrator Acceptance [ Time Frame: 20 minutes ]
    The person administering drug will rate their experience by completing a questionnaire 20 minutes after each dose.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males or females aged 18-65 years.
  • Good general health without clinically significant renal, hepatic, cardiac or respiratory disease, as determined by the Principal Investigator.
  • Willing and able to give informed consent and agree to complete all study procedures.
  • Have suitable venous access for blood sampling.
  • Female participants are eligible only if all the following apply:

    1. Not pregnant (women of child bearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test at check-in for each inpatient period);
    2. Not lactating;
    3. Not planning to become pregnant during the study;
    4. Be surgically sterile (irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or have undergone bilateral tubal ligation; or be at least two years post-menopausal; or is practicing double-barrier contraception or is using an insertable, injectable, transdermal, or combination oral contraceptive for greater than 2 months prior to screening visits and commits to the use of an acceptable form of highly effective birth control for the duration of the study and for 30 days after the last dose study drug administration.
  • BMI within the range of 19-30 kg/m2 (inclusive).
  • Deemed able to read and understand English in order to communicate with research staff and complete protocol required questionnaires and forms.

Exclusion Criteria:

  • Has a laboratory value at the Screening Visit that is outside the normal range, unless it is judged by the Investigator as not clinically significant after appropriate evaluation. One repeat of initial laboratory testing is allowed.
  • AST, ALT and ALP tests in excess of 1.5 times the upper limit of normal.
  • Any gastrointestinal condition that could affect drug absorption.
  • History of any clinically significant condition involving the bladder or urinary tract, including frequent urinary tract infections (e.g. > 2 per year), or current symptoms of bladder irritation such as frequent or urgent need to urinate or burning with urination.
  • History (within the last six months) of or current clinically significant psychiatric disorder including anxiety, psychosis or depression.
  • Current inflammatory or ulcerative disease of the oral cavity that could impair the absorption of sublingual medication.
  • History of severe allergic or anaphylactic drug-related reactions.
  • History of hypersensitivity to ketamine or any of the excipients of Wafermine™.
  • Intake of any prescribed or Over-The-Counter (OTC)/non-prescribed drugs, vitamins, supplements or herbal medicines, within 2 weeks of administration of investigational product (or longer if the medication has a half-life long enough to potentially expose the healthy participant to any significant systemic exposure). Exception: Hormone replacement therapy and oral contraceptives in female participants is allowed.
  • Use of drugs with enzyme-inducing properties, such as rifampicin and St John's Wort, within 3 weeks or 5 half-lives, whichever is greater, prior to treatment period 1 and throughout the study, or any drug known to be a strong inhibitor of CYP3A4 within 5 half-lives of treatment period 1 and throughout the study.
  • Participation in another clinical trial of an investigational agent within 30 days of screening.
  • Positive serology for hepatitis C virus (HCV), hepatitis B or human immunodeficiency virus (HIV).
  • Clinically significant, as determined by the Investigator, abnormal ECG (12-lead) or vital signs at the screening visit or pre-dose on any treatment day.
  • Known or suspected drug (including analgesic drugs or tranquilizers) or alcohol abuse or dependence, as defined by DSM-IV, and not in full remission, as judged by the Investigator, or history of alcohol abuse or excessive intake of alcohol, defined as regular weekly intake of >15 units for men and >10 units for women. (1 unit = 25 mL spirits, 125 mL wine, 250 mL beer or lager.)
  • Positive results on the urine drug screen or breath alcohol test at screening and/or pre-dose. A positive result on the urinary drug screen at screening is allowed at the discretion of the Investigator provided the result can be reliably explained by recent medication and/or dietary history.
  • Significant history of illicit drug use (as determined by the Investigator).
  • Any alcohol use within 24 hours prior to each inpatient treatment period.
  • Unwillingness or inability to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the participant returning for subsequent visits on schedule.
  • Blood donation (1 unit or more) within 1 month prior to the screening visit and until the end of study participation.
  • Current or previous tobacco user (within 12 months prior to screening).
  • Participants who routinely consume more than four standard caffeinated beverages per 24-hour period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02857361

Layout table for location information
Australia, Western Australia
Linear Clinical Research
Nedlands, Western Australia, Australia, 6009
Sponsors and Collaborators
iX Biopharma Ltd.
Layout table for investigator information
Principal Investigator: Sam Salman, MD iX Biopharma

Layout table for additonal information
Responsible Party: iX Biopharma Ltd. Identifier: NCT02857361     History of Changes
Other Study ID Numbers: KET011
First Posted: August 5, 2016    Key Record Dates
Last Update Posted: August 19, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action